Category Archives: Deals

Is There Life After Big Pharma?

By Julian Upton | Published: March 11, 2010
Guest blog by Pharm Exec Europe’s Jacky Law. It’s hard to get precise figures of how many people have been taken off the payroll at pharma and biotech companies recently. According to staffing firm, Challender, Gray and Christmas, the combined industries shed 58,969 jobs in the first nine months of 2009, 15,000 more than the whole [...]
Also posted in Corporate Responsibility, Europe, Global, Guest Blog | Tagged , , , , , | Leave a comment

GSK Signs $120M Deal to Market DMab Overseas

By George Koroneos | Published: July 29, 2009
Image via Wikipedia In an effort to boost its sales force without hiring more sales reps, Amgen announced on Tuesday that it has signed a deal with GlaxoSmithKline to co-market its osteoporosis treatment denosumab—currently pending FDA approval. GSK will paying $120 million up front (along with royalties) to mutually market denosumab, or DMab, in regions where Amgen [...]
Also posted in News, Technology | Tagged , , , , , , , , , , , | Leave a comment

M&A Round-up • 3/25/2009

By George Koroneos | Published: March 25, 2009
The latest round of merger and acquisition activities courtesy of our friends at Pharm Exec Europe: • Just days after its purchase of Genentech, Roche has made another acquisition, albeit a much smaller one, of the German firm Innovatis. Roche will pay EUR 15 million for the cell analytics company. • Oxford Gene Technology (OGT) is to [...]
Posted in Deals | Tagged , , , , , , , , , , | Leave a comment

Gilead Buys CV Therapeutics (Update 1)

By Walter Armstrong | Published: March 16, 2009
The morning’s other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that it will purchase CV Therapeutics for $1.4 billion. The sudden move frees Palo Alto-based cardiovascular company CV Therapeutics from the hostile embrace of Astellas Pharma, ending a messy $1.1 billion takeover attempt. With the acquisition, Gilead, [...]
Posted in Deals | Tagged , , , , , , , | 1 Comment

Merck/Schering-Plough Merger Highlights (Update 1)

By George Koroneos | Published: March 9, 2009
Merck and Schering-Plough’s CEOs are giving a run down of the benefits of the $41.1 billion merger, announced this morning, in a conference call with investors. Here are some of the highlights: • Total price of the sale will be $41.1 billion or $23.6 per Schering share. • This deal is structured as a reverse merger with [...]
Also posted in Strategy | Tagged , , , , , , | 4 Comments